Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
35 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Sperimentazione conclusa
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
PAESI BASSI
Zuid-Holland
ROTTERDAM
COMPARE 60/80 HBR: Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population
Maasstad Ziekenhuis
Polikliniek Cardiologie
GERMANIA
Berlin
BERLIN
ALL-REZ BFM 2002: Multicentre Study for Children With Relapsed Acute Lymphoblastic Leukemia
Otto-Heubner-Centrum für Kinder- und Jugendmedizin
Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie
GERMANIA
Niedersachsen
GÖTTINGEN
DSHNHL 2006-1B (ACT-2): Randomized phase III trial will evaluate the efficacy of Chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 6 courses of 2-weekly CHOP, versus standard Chemotherapy with 2-weekly CHOP alone in elderly patients with peripheral T-cell lymphomas (A-CHOP-14) - DE
Universitätsmedizin Göttingen
Klinik für Hämatologie und Medizinische Onkologie
SPAGNA
Cataluña
BARCELONA
Immunotherapy with differential, adult, autologous, peripheral blood cells, expanded and transduced (genetically modified) using a lentiviral vector to express a chimeric receptor with anti-CD30 specificity associated with costimulatory sequences 4-1-BB and CD3z in patients with Classical Hodgkin's lymphoma and non-Hodgkin's lymphoma T with CD30 expression - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Hematología
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase I/IIa study of intra-tumoral BT-001 (TG6030) administered alone and in combination with pembrolizumab in patients with cutaneous or, subcutaneous lesions or easily injectable lymph nodes of metastatic/advanced solid tumors - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service d'oncologie médicale
FRANCIA
ILE-DE-FRANCE
VILLEJUIF
Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin's Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia
CLCC Institut Gustave Roussy
Département d'hématologie
FRANCIA
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid®) With Rituximab in Subjets With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma (Phase II) - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
GERMANIA
Baden-Württemberg
HEIDELBERG
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Deutsches Krebsforschungszentrum
Klinische Kooperationseinheit Pädiatrische Onkologie
GERMANIA
Bayern
REGENSBURG
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Regensburg
Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation
GERMANIA
Bayern
WÜRZBURG
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Würzburg
GERMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
PIVOT IO 020: Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies - DE
Institution: Information not provided - DE
GERMANIA
Berlin
BERLIN
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Charité - Universitätsmedizin Berlin
GERMANIA
Nordrhein-Westfalen
ESSEN
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Essen
Klinik für Kinderheilkunde III
GERMANIA
Nordrhein-Westfalen
MÜNSTER
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Münster
GERMANIA
Sachsen
LEIPZIG
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Follow-up di studio di fase I/II sull'impiego di cellule T CaspaCide derivate da donatore familiare parzialmente compatibile sottoposto a procedura di T deplezione alfa-beta, in pazienti pediatrici affetti da disordini ematologici dopo trapianto aploidentico
Institution: Information not provided - IT
ITALIA
LAZIO
ROMA
CD19-CAR01: Studio di fase I/II sull'espressione in cellule T di un recettore chimerico anti-CD19 in pazienti pediatrici affetti da Leucemia Linfoblastica Acuta CD19+ recidivata/refrattaria e Linfoma non Hodgkin
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
ITALIA
LOMBARDIA
ROZZANO
Studio prospettico di fase II di terapia mieloablativa ad alte dosi, con supporto di cellule staminali periferiche, in pazienti anziani (tra 65 e <76 anni) affetti da linfoma non Hodgkin aggressivo recidivato o resistente alla terapia di prima linea
IRCCS Istituto Clinico Humanitas
U.O. Oncologia Medica ed Ematologia
ITALIA
PIEMONTE
TORINO
Studio di fase II con Bortezomib, Rituximab e Bendamustina -BRB- in pazienti affetti da linfoma non Hodgkin linfoplasmocitico/morbo di Waldenstrom alla prima recidiva
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette
S.C. di Ematologia
REGNO UNITO; GRAN BRETAGNA
Cambridgeshire
CAMBRIDGE
UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma -GB
Addenbrooke's Hospital
Cambridge Cancer Trials Centre
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
UK Haplo v1.0: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
Guy's Hospital
Department of Haematology
REGNO UNITO; GRAN BRETAGNA
Greater London
UXBRIDGE
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
UNITY: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin' s Lymphoma - ES
Institution: Information not provided - ES
SVIZZERA
Suisse Italienne
BELLINZONA
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - BRUIN - CH
Ospedale Regionale di Bellinzona e Valli
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
COVID-19: A Phase 3, open-label, parallel group, multicenter clinical study to evaluate the safety, reactogenicity, and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in participants 45 years or older with either a solid tumor or hematologic malignant disease who are receiving or scheduled to receive systemic anticancer therapy (independent of intent) - AT
Institution: Information not provided - AT
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-label, Phase I/II Study to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Anticancer Activity of Avelumab in Pediatric Subjects From Birth to Less Than 18 Years of Age With Refractory or Relapsed Solid Tumors and Lymphoma - BE
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
ITALIA
LAZIO
ROMA
Studio in aperto, a braccio singolo, di fase 1/2 che valuta la sicurezza e l'efficacia di Ponatinib per il trattamento delle leucemie ricorrenti o refrattarie o dei tumori solidi in pazienti pediatrici
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
Sperimentazioni cliniche internazionali
SPAGNA
Madrid
COLMENAR VIEJO
A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (coordination)
PharmaMar S.A.
Pharma Mar S.A.
STATI UNITI
New Jersey
SUMMIT
STATI UNITI
Texas
HOUSTON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Institution: Information not provided - US
SVIZZERA
Suisse Alémanique
BASEL
An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma (Phase II) (coordination)
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SPAGNA
Madrid
COLMENAR VIEJO